incretin GLP-1
Selected indexed studies
- Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. (Front Endocrinol (Lausanne), 2024) [PMID:39114288]
- GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management. (Nat Metab, 2024) [PMID:39160334]
- Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment. (Pharmacol Res, 2022) [PMID:36372278]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update. (2021) pubmed
- Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. (2024) pubmed
- Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver. (2023) pubmed
- Incretin hormones: Their role in health and disease. (2018) pubmed
- Tirzepatide: A Systematic Update. (2022) pubmed
- GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management. (2024) pubmed
- Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment. (2022) pubmed
- GLP-1, a powerful physiological incretin: an update. (2018) pubmed
- GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. (2017) pubmed
- GLP-1 and Underlying Beneficial Actions in Alzheimer's Disease, Hypertension, and NASH. (2021) pubmed